Literature DB >> 20472113

Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.

Carolyn L Westhoff1, Anupama H Torgal, Elizabeth R Mayeda, Malcolm C Pike, Frank Z Stanczyk.   

Abstract

BACKGROUND: This study was conducted to compare oral contraceptive (OC) pharmacokinetics (PK) in normal-weight [body mass index (BMI) 19.0-24.9] and obese (BMI 30.0-39.9) women. STUDY
DESIGN: During the third week of the third cycle of OC use, we admitted 15 normal-weight and 15 obese women for collection of 12 venous specimens over 24 h. Using radioimmunoassay techniques, we measured levels of ethinyl estradiol (EE) and levonorgestrel (LNG). During the same cycle, women underwent twice-weekly sonography to assess ovarian follicular development and blood draws to measure endogenous estradiol (E2) and progesterone levels.
RESULTS: Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups. The similar, but smaller, differences in their LNG levels for AUC and maximum values (C(max)) were not statistically significant. While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively). Women with greater EE AUC had smaller follicular diameters (p=.05) and lower E2 levels (p=.04). While follicular diameters tended to be larger among obese women, these differences were not statistically significant.
CONCLUSION: OC hormone peak levels are lower among obese women compared to normal-weight women, but their trough levels are similar. In this small study, the observed PK differences did not translate into more ovarian follicular activity among obese OC users.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472113      PMCID: PMC3522459          DOI: 10.1016/j.contraception.2010.01.016

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics.

Authors:  M H Rahimy; M A Cromie; N K Hopkins; D M Tong
Journal:  Contraception       Date:  1999-10       Impact factor: 3.375

2.  Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration.

Authors:  F Z Stanczyk; M Hiroi; U Goebelsmann; P F Brenner; M E Lumkin; D R Mishell
Journal:  Contraception       Date:  1975-09       Impact factor: 3.375

Review 3.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

4.  Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins.

Authors:  Joseph W Goldzieher; Frank Z Stanczyk
Journal:  Contraception       Date:  2008-06-02       Impact factor: 3.375

Review 5.  Drug pharmacokinetics in the obese.

Authors:  G Cheymol
Journal:  Fundam Clin Pharmacol       Date:  1988       Impact factor: 2.748

6.  Pharmacokinetics of Implanon. An integrated analysis.

Authors:  J Huber; R Wenzl
Journal:  Contraception       Date:  1998-12       Impact factor: 3.375

7.  Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants.

Authors:  I Sivin; L Wan; S Ranta; F Alvarez; V Brache; D R Mishell; P Darney; A Biswas; S Diaz; O Kiriwat; M P Anant; C Klaisle; M Pavez; J Schechter
Journal:  Contraception       Date:  2001-07       Impact factor: 3.375

8.  Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.

Authors:  T M Price; R E Dupuis; B R Carr; F Z Stanczyk; R A Lobo; W Droegemueller
Journal:  Am J Obstet Gynecol       Date:  1993-05       Impact factor: 8.661

9.  Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.

Authors:  Alison B Edelman; Nichole E Carlson; Ganesh Cherala; Myrna Y Munar; Richard L Stouffer; Judy L Cameron; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2009-06-04       Impact factor: 3.375

Review 10.  Obesity and oral contraceptive pill failure.

Authors:  James Trussell; Eleanor Bimla Schwarz; Katherine Guthrie
Journal:  Contraception       Date:  2009-01-17       Impact factor: 3.375

View more
  35 in total

1.  Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions.

Authors:  John T Barr; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2011-09-22       Impact factor: 3.922

2.  Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women.

Authors:  Carolyn L Westhoff; Anupama H Torgal; Elizabeth Rose Mayeda; Kelsey Petrie; Tiffany Thomas; Monica Dragoman; Serge Cremers
Journal:  Am J Obstet Gynecol       Date:  2012-04-28       Impact factor: 8.661

3.  Estimating systemic exposure to levonorgestrel from an oral contraceptive.

Authors:  Cale N Basaraba; Carolyn L Westhoff; Malcolm C Pike; Renu Nandakumar; Serge Cremers
Journal:  Contraception       Date:  2016-12-30       Impact factor: 3.375

Review 4.  Obesity and contraception.

Authors:  Sheila K Mody; Michelle Han
Journal:  Clin Obstet Gynecol       Date:  2014-09       Impact factor: 2.190

Review 5.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 6.  Perspectives on variability in pharmacokinetics of an oral contraceptive product.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-07-27       Impact factor: 3.375

7.  Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.

Authors:  Teresa Barcellos; Melissa Natavio; Frank Z Stanczyk; Dandan Luo; William J Jusko; Nicole M Bender
Journal:  Contraception       Date:  2019-06-10       Impact factor: 3.375

8.  Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.

Authors:  Marcia A Ciccone; Stephanie A Whitman; Charlotte L Conturie; Niquelle Brown; Christina E Dancz; Begum Özel; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2019-01-31       Impact factor: 2.344

9.  Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.

Authors:  Alison B Edelman; Ganesh Cherala; Myrna Y Munar; Barent Dubois; Martha McInnis; Frank Z Stanczyk; Jeffrey T Jensen
Journal:  Contraception       Date:  2012-11-12       Impact factor: 3.375

10.  Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys.

Authors:  Kate A Shaw; Jon D Hennebold; Alison B Edelman
Journal:  Contraception       Date:  2012-12-04       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.